Zenocutuzumab-zbco (Bizengri)
Dilution requiredFull monograph review pending
U.S. label preparation
Bizengri · Dilution required
- Preparation
- Replace 37.5 mL from a 250 mL 0.9% sodium chloride bag with 37.5 mL of drug drawn from two vials. Final volume is 250 mL.
- Administration and handling
- Use the specified 0.2-micron PES filter. See section 2.7 for time limits that include administration.
Product and source details
Merus US, Inc. · BLA761352
Product NDC: 83077-100
SPL effective 2025-01-17 | SPL version 2. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.